Fidelity Investments’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$361K Sell
32,674
-2,923
-8% -$45.1K ﹤0.01% 3247
2025
Q4
$725K Sell
35,597
-64,934
-65% -$1.14M ﹤0.01% 2963
2025
Q3
$1.59M Sell
100,531
-63,740
-39% -$942K ﹤0.01% 2630
2025
Q2
$2.19M Sell
164,271
-277,269
-63% -$3.74M ﹤0.01% 2457
2025
Q1
$4.5M Sell
441,540
-5,101,768
-92% -$59.2M ﹤0.01% 2186
2024
Q4
$87.8M Buy
5,543,308
+644,174
+13% +$33.5M 0.01% 1172
2024
Q3
$284M Buy
4,899,134
+179,374
+4% +$8.86M 0.02% 688
2024
Q2
$216M Sell
4,719,760
-298,756
-6% -$16.1M 0.01% 758
2024
Q1
$332M Buy
5,018,516
+1,144,312
+30% +$67.9M 0.02% 590
2023
Q4
$154M Buy
3,874,204
+269,276
+7% +$8.44M 0.01% 851
2023
Q3
$115M Sell
3,604,928
-454,113
-11% -$17M 0.01% 912
2023
Q2
$163M Buy
4,059,041
+7,168
+0.2% +$314K 0.01% 804
2023
Q1
$173M Buy
4,051,873
+372,784
+10% +$18.8M 0.02% 766
2022
Q4
$177M Sell
3,679,089
-184,437
-5% -$8.62M 0.02% 737
2022
Q3
$145M Buy
3,863,526
+263,631
+7% +$9.14M 0.02% 806
2022
Q2
$99.5M Buy
3,599,895
+591,959
+20% +$26M 0.01% 974
2022
Q1
$164M Sell
3,007,936
-496,862
-14% -$25.5M 0.01% 861
2021
Q4
$205M Buy
3,504,798
+4,119
+0.1% +$205K 0.02% 798
2021
Q3
$138M Buy
3,500,679
+6,140
+0.2% +$219K 0.01% 969
2021
Q2
$148M Buy
3,494,539
+566,422
+19% +$30.7M 0.01% 938
2021
Q1
$180M Buy
2,928,117
+283,497
+11% +$18M 0.02% 827
2020
Q4
$187M Buy
2,644,620
+856,075
+48% +$53.9M 0.02% 772
2020
Q3
$69M Buy
1,788,545
+428,873
+32% +$17M 0.01% 1079
2020
Q2
$51M Buy
+1,359,672
New +$41.9M 0.01% 1155

Other funds holding KROS